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The records of 90 patients with Wolff-Parkinson-White
syndrome who presented with supraventricular tachy-
cardia in the first 4 months of life were reviewed. Among
these, 63% were male. Structural heart disease was pres-
ent in 20%, most commonly Ebstein's anomaly. All pa-
tients presented with a regular narrow QRS tachycardia,
and pre-excitation became evident only when normal
sinus rhythm was established. Only one infant had atrial
flutter and none had atrial fibrillation. Type A Wolff-
Parkinson-White syndrome was most common (49%),
with heart disease occurring in only 5% of these patients.
In contrast, heart disease was identified in 45% of those
with type B syndrome.
Initially, normal sinus rhythm was achieved in 88%
of the 66 infants treated with digoxin with no deaths.
Normal sinus rhythm resumed after electrical counter-
shock in 87% of the 15 infants so treated. Maintenance
digoxin therapy was used in 85 patients. The Wolff-
Parkinson-White pattern disappeared in 36% ofthe pa-
tients. Four infants died of cardiac causes during the
The Wolff-Parkinson-White syndrome is present in 10 to
50% of infants with supraventricular tachycardia (1-5). Di-
goxin has been the standard recommended therapy for these
infants (2,6), in contrast to adult patients (7-9). Among
patients presenting with this syndrome in early infancy,
recurrences after the first 18 months of life are thought
unlikely (2,5,6,10), and previous investigators (6) have
stressed the benign course of the syndrome in patients with-
out structural heart disease, Only limited information is
available concerning the long-term outcome in such infants,
including the persistence of the electrocardiographic pattern,
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mean follow-up period of 6.5 years. Two of these four
infants had congenital heart disease; the third, with a
normal heart initially, developed ventricular fibrillation
and died from a cardiomyopathy considered related to
resuscitation. The remaining infant, with a normal heart,
died suddenly at 1 month of age. All were receiving
digoxin. A wideQRS tachycardia later appeared in three
patients, all with heart disease, one of whom died.
In the initial treatment of narrow regular QRS supra-
ventricular tachycardia in this group of patients, digoxin
was a safe and effective (88%) drug for restoration of
normal sinus rhythm, with electrical cardioversion being
equally effective (87%) in those critically ill. After age
1 year, 33% of the infants experienced recurrent tachy-
cardias; these were more frequent in patients with type
B Wolff-Parkinson-White syndrome (p < 0.05) and in
those requiring more than one drug to maintain normal
sinus rhythm during the initial hospitalization (p < 0.001).
(J Am Coil CardioI198S;S:130-S)
the incidence of recurrent supraventricular tachycardia and
the results of therapy (3,4,6,11,12).
Because controversy exists about the use of digoxin, we
reviewed the data on all infants presenting with supraven-
tricular tachycardia and Wolff-Parkinson-White conduction
to our institutions over the last 31 years. In addition. we
attempted to evaluate prognostic factors and the outcome
of various treatment regimens, particularly digitalis therapy,
Methods
Patients. The records of all patients with the diagnosis
of Wolff-Parkinson-White syndrome observed at the Texas
Children's Hospital, Houston and the Children's Hospital.
Boston between 1951 and 1982 were reviewed. Among
these. 90 infants were identified who had a prolonged ep-
isode of tachycardia in the first 4 months of life and are the
subject of this report. The electrocardiographic diagnosis of
Wolff-Parkinson-White syndrome in normal sinus rhythm
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Table 1. Cardiac Lesions in Infants With Wolff-Parkinson-
White Syndrome andSupraventricular Tachycardia
Results
Clinical features. Of the 90 infants, 57 (63%) were
male and 33 were female (p < 0.05). No structural heart
disease was present in 72 patients (80%), while heart disease
was identified in 18 (20%) (Table I). Among the latter, IO
were female and Ebsteins anomaly was the most common
lesion encountered (5 patients).
Pattern of presentation. All patients presented initially
with tachycardia, and Wolff-Parkinson-White conduction
was based on a short PR interval for age (:50.08 second),
a prolonged QRS complex (> 0.08 second) and a delta
wave. The electrocardiograms were classified into type A
(positive delta wave and positive QRS complex in right
precordial leads, simulating right bundle branch block), type
B (positive delta wave and positive QRS complex in left
precordial leads, resembling left bundle branch block) and
type C (positive delta wave, positive QRS complex in leads
VI to V6 ) (12,13).
Among the 90 infants, 48 were seen at Texas Children' s
Hospital and the other 42 at Children's Hospital in Boston.
A complete history, physical examination, chest roentgen-
ogram and electrocardiogramwere obtained for each patient;
more thorough investigations were made in those patients
with evidence of underlying heart disease. Complete 12 lead
electrocardiograms taken during the initial episode of tachy-
cardia were available for analysis in 65 patients; rhythm
strips were available in the remaining 25. All patients had
complete electrocardiograms after conversion to normal sinus
rhythm.
Follow-up. This included a detailed history of the fre-
quency of tachycardia episodes, a record of all medications
taken, electrocardiograms (obtained in 89 patients) and fur-
ther tests as indicated. Contact by telephone or letter was
attempted for any patient not seen within the last 3 years.
Statistics. Statistical analysis of continuous data was
performed using the Student' s t test; categorical data were
evaluated using chi-square analysis.
PAPVC = partial anomalous pulmonary venous connection: PS
pulmonary stenosis; VSD = ventricular septal defect.
Lesion
Ebstein' s anomaly
Patent ductus arteriosus
Cardiomyopathy
Corrected transposition of
great arteries
Mitral insufficiency + VSD
Single ventricle +- PS
Aortic stenosis
VSD
PAPVC
No. of Patients
5
3
3
2
was first noted only after conversion to normal sinus rhythm.
The mean age at presentation was 29 days, with 69% pre-
senting in the first month of life. Tachycardia was detected
in utero in seven patients (8%), two of whom were delivered
by emergency cesarean section for congestive heart failure.
Signs of congestive heart failure were the presenting features
in 54% of the patients (49 of 90); most asymptomatic infants
had the arrhythmia identified during a routine evaluation.
Three patients presented in shock that in two of the three
progressed to cardiac arrest from which they were success-
fully resuscitated. In addition, two infants underwent an
exploratory laparotomy for unexplained neonatal ascites be-
fore the tachycardia and then the Wolff-Parkinson-White
pattern became manifest on electrocardiogram.
Electrocardiogram. During the initial episode oftachy-
cardia. the heart rate was regular in all infants with rates
ranging from 215 to 350 beats/min (mean 280); the QRS
complex was narrow in all. There was no correlation be-
tween heart rate during tachycardia and the presence of heart
disease. No arrhythmia other than supraventricular tachy-
cardia was identified with the exception of one occurrence
of atrial flutter. Subsequently, three patients developed a
wide QRS tachycardia (QRS interval > 0 .12 second).
Classification of Wolff-Parkinson-White pattern . A
summary of the types of Wolff-Parkinson-White pattern on
the electrocardiogram for all patients and for those with
heart disease is presented in Table 2. It can be seen that
although type A was most common (49%), only II % of
patients with heart disease had this pattern. In contrast. type
B (present in 32% of all patients and in 22% of those with
a normal heart) was by far the most common pattern seen
in those with heart disease (72%). Among all patients with
type B Wolff-Parkinson-White conduction, 45% were found
to have heart disease. compared with 5% of patients with
type A (p < 0.001) and 13% of patients with type C (p <
0.05).
Initial treatment. Table 3 outlines the methods used to
obtain normal sinus rhythm during the initial episode of
supraventricular tachycardia. Spontaneous conversion to sinus
rhythm occurred in eight patients, whereas normal sinus
rhythm was achieved in 58 (88%) of 66 infants treated with
digoxin and 13 (87%) of 15 patients treated with electrical
countershock. After conversion to normal sinus rhythm, five
Table 2. Classification of Wolff-Parkinson-White Patterns
Patients With Patients With
All Patients Normal Heart Heart Disease
( n = 90) (n = 72) In = IX)
Type No. (% ) No. (%) No . 1%)
A 44(49) 42(5X) 2(II )
B 29(2 ) [6(22 ) 13( 2 )
C 16(IX) 14(20) 2( II )
A + B /( I ) 0 1(6)
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Table 4. Mortality in the Patients StudiedTable 3. Methods of Conversion to Normal Sinus Rhythm
During Initial Supraventricular Tachycardia
Age at Death Circumstance Card iac Lesions
Spontaneous conversion
Digoxin administration
Electrical cardioversion
Other*
Total
No. of Patients (%)
8(9)
58(65)
13(14)
11(12)
90(100 )
I mo
4 mo
6 mo
18 yr
15 yr
Dead in crib
During tachycardia
SYT, YF
SYT. YF
Acciden tal
None
Single left ventricle
(d-loop) and PS
Cardiomyopathy
Ebste in' s anomaly
None
*Includes admini stration of multiple drugs (six patients ), vagal ma-
neuvers (one patient) ; ice to forehead (one patient), verapamil (one patient),
methoxamine (one patient ) and phenylephrine (one patient).
PS = pulmonary stenosis; SYT
YF = ventricular fibrillation .
supraventricular tachycardia;
25
2 3 5 10 15 20
YEARS
Figure 1. Duration of follow-up (in years) of patients after first
documented episode of supraventricular tachycardia. Median =
4.5 years.
of the eight patients whose arrhythmia converted sponta-
neously were discharged taking no medication; all of the
remaining 85 infants received digoxin. Among these infants,
15 required the addition of one or more drugs to maintain
sinus rhythm during their initial hospitalization. No deaths
occurred during treatment of this initial episode of supra-
ventricular tachycardia.
In the third patient , with type B conduction , supraven-
tricular tachycardia at birth was converted by treatment with
digoxin, which was continued as maintenance therapy. On
the basis of physical examination and chest roentgenogram,
there was no evidence of heart disease at this time. At 2
months of age, she had a cardiac arrest outside the hospital
and received several electrical countershocks up to 75 watt-
s/dose for recurrent ventricular fibrillation for the next 2
days. She died at 6 months of age and was found to have
a cardiomyopathy thought to be related to the high electrical
cardioversion doses.
The f ourth patient, with Ebstein's anomaly and type B
Wolff-Parkinson-White conduction, developed frequent
symptomatic supraventricular tachycardia with a wide QRS
complex; this represented the antidromic form of accessory
pathway conduction. He was treated with digoxin and quin-
idine and had multiple admissions for electrical cardiover-
sion. During one of these admissions , supraventricular
tachycardia degenerated to ventricular fibrillation and the
patient died at 18years of age. Neither digoxin nor quinidine
serum levels were available in these four patients; although
they were receiving standard doses, it is not possible to
exclude drug toxicity as acontributing factor in their deaths.
The remaining patient died because of an accident.
Wide QRS tachycardia. Three patients, each with heart
disease, developed a wide QRS tachycardia during subse-
quent episodes of supraventricular tachycardia; the first is
the fourth patient just described. A second patient, also with
Ebstein's anomaly, had brief recurrent episodes of narrow
complex supraventricular tachycardia in the first year of life
and was maintained on digoxin therapy for 8 years. At 9
years of age, without digoxin treatment, she developed a
wide QRS tachycardia (antidromic conduction) with chest
pain, requiring electrical cardioversion. Digoxin therapy was
resumed but she continued to have frequent symptomatic
episodes of wide QRS tachycardia , later accompanied by
atrial fibrillation at age 24 years. Digoxin was discontinued ,
and after failure of quinidine and propranolol therapy, she
is how well controlled with amiodarone treatment alone.
The third patient was born with atrial flutter. the only
patient with this arrhythmia in this series. Later, while re-
ceiving digoxin, she developed a wide QRS tachycardia
along with a variety of atrial arrhythmias including atrial
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FoLLow-Up
The 90 patients were followed up from 0.5 months to
27 years (mean 6.5 years) (Fig. 1). The Wolff-Parkinson-
White pattern persisted in 64% (57 of 89) of the patients,
and was not seen again in the other 36%.
Mortality. There were five deaths during this period
(Table 4): all five patients were receiving digoxin. The first
patient presented with tachycardia at birth and was main-
tained on digoxin therapy after successful conversion to
normal sinus rhythm with this drug. This infant with type
A conduction was found dead in his crib at I month of age.
Postmortem examination was unrevealing . The second pa-
tient had severe cyanotic congenital heart disease, type B
Wolff-Parkinson-White conduction and had undergone a
Potts shunt 10days before dying during an episode of tachy-
catdia on the way to the hospital. The patient was receiving
digoxin and quinidine.
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fibrillation-flutter. This patient was successfully treated with
and maintained on procainamide after failure of cardio-
version and propranolol therapy.
Recurrent supraventricular tachycardia. Among the
90 infants, 37 (41%) experienced supraventricular tachy-
cardia as a single episode or as brief recurring episodes only
during their initial hospitalization. Another 30 patients (33%)
continued to have recurrent supraventricular tachycardia after
I year of age. All 30 patients also continued to have re-
currences beyond 18 months. Twenty-five (42%) of 60 pa-
tients followed up for more than 2 years continued to have
recurrent episodes of tachycardia. Recurrence of tachycardia
after I year of age was not related to sex, presence of heart
disease (with the exception of Ebstein's anomaly) or persist-
ence of Wolff-Parkinson-White pattern on the electrocar-
diogram (chi-square analysis). Recurrences were signifi-
cantly more likely to occur in patients with type B Wolff-
Parkinson-White conduction than in those with type A
(p < 0.05) or type C (p < 0.05) and in those requiring two
or more drugs to maintain normal sinus rhythm during pre-
sentation (p < 0.001). Among patients with type B con-
duction, 45% had recurrent supraventricular tachycardia after
I year of age, compared with 25% of patients with type A
and 20% with type C conduction. Three-fourths of patients
requiring multiple drugs initially continued to have late re-
currences, as did four of the five with Ebstein' s anomaly.
Maintenance therapy. Two patients had no further ep-
isodes of supraventricular tachycardia after spontaneous
conversion to normal sinus rhythm and received no medi-
cation. Digoxin was the only medication used in 55 patients
(61%); 33 patients (37%) required additional therapy to
control recurrent supraventricular tachycardia. Among the
15 patients recei ving multiple drugs to maintain constant
normal sinus rhythm at presentation, II continued to have
recurrent supraventricular tachycardia beyond I year of age;
6 required additional medical therapy and 2 eventually
underwent surgical division of the bypass tract. In contrast,
only IS of the 70 infants managed initially with digoxin
alone required additional medical therapy.
In patients experiencing frequent recurrent supraven-
tricular tachycardia while receiving digoxin, various com-
binations of digoxin, quinidine and propranolol were used
to maintain normal sinus rhythm. In addition, one patient
with Ebstein's anomaly with recurrent symptomatic epi-
sodes of wide QRS supraventricular tachycardia while tak-
ing these medications is now well controlled with amio-
darone alone. Verapamil was successful in one of three
patients in whom it was tried after failure of digoxin, quin-
idine and propranolol therapy.
Three patients underwent surgery for division of Kent
bundles after failure of medical therapy. Postoperatively,
two patients have had no recurrences of supraventricular
tachycardia without medication, with disappearance of the
Wolff-Parkinson-White pattern on the electrocardiogram.
The third patient has had a decrease in episodes of tachy-
cardia, but continues to have the pre-excitation pattern.
Electrophysiologic studies. Twenty patients underwent
22 studies at Texas Children's Hospital; most have been
previously reported (14). The anterograde effective refrac-
tory periods of the accessory connection and the atrioven-
tricular node were measured in 14 and 5 patients, respec-
tively; in eight more recent studies, the response of the
refractory period to ouabain administration was determined
as a guide to future therapy with digoxin. The anterograde
effective refractory period of the accessory connection was
longer than 200 ms in all but one (170 ms) and exceeded
that of the atrioventricular node in three patients in whom
both measurements were available. After ouabain admin-
istration, the anterograde effective refractory period of the
accessory connection decreased in four «200 ms in one),
increased in three and was unchanged in one patient. One
patient with Ebstein's anomaly developed rapid anterograde
conduction over the accessory pathway with atrial fibrilla-
tion during the study after receiving ouabain; her therapy
was therefore changed from digoxin to quinidine.
No accessory pathway could be identified in two patients
in whom the electrocardiographic pattern of Wolff-
Parkinson-White conduction had disappeared; in one of these,
an accessory pathway had been documented previously.
Discussion
Analysis of this series of 90 infants with Wolff-Parkin-
son-White conduction and supraventricular tachycar-
dia confirms the previously reported male preponderance
(3,6,10) and the incidence of congenital heart disease in
approximately 20% of patients (6,10,11). Although clas-
sification of Wolff-Parkinson-White conduction into three
types may be of some use in localizing the bypass tracts
(7,15,16), it has not been thought to be clinically helpful
in patient management (12,17). In our patients with Wolff-
Parkinson-White syndrome presenting with supraventricular
tachycardia in early infancy, type A conduction was most
common (49%), was associated with heart disease in only
5% of patients and had a relatively low risk of recurrent
supraventricular tachycardia (25%) after I year of age. Type
B conduction occurred in about one-third of our infants and
was associated with a high incidence of both heart disease
(45%) and recurrent supraventricular tachycardia (45%).
Overall, the Wolff-Parkinson-White pattern disappeared on
subsequent electrocardiograms in 36% of the patients; how-
ever, recurrent supraventricular tachycardia was not signif-
icantly less in these children, perhaps because of the small
number of patients in this group or because retrograde con-
duction only over the accessory pathway persisted. In one
patient, the accessory pathway could not be detected at a
subsequent electrophysiologic study. Therefore, at least in
134 DEALET AL.
SUPRAVENTRICULAR TACHYCARDIA IN INFANCY
JACC Vol. 5. No. I
January 1985:130--5
the infants and children, classification of Wolff-Parkinson-
White conduction into types may provide useful diagnostic
and prognostic information.
Treatment of Supraventricular Tachycardia: Use of
Digitalis and Recommendations
It is well documented that in adults, atrial fibrillation
may be associated with rapid anterograde conduction over
the accessory pathway, leading to ventricular fibrillation
(7,9,17-19). It has also been shown (9,18,20) that digitalis
may shorten the anterograde refractory period of the acces-
sory pathway and result in ventricular fibrillation in both
adults and children.
Initial episode of supraventricular tachycardia. All
of our patients presented initially with tachycardia, and Wolff-
Parkinson-White conduction became evident only after con-
version to normal sinus rhythm. No patient was found to
have either atrial fibrillation or a wide QRS tachycardia at
onset, although a single neonate with these features was
recently reported (21). Digoxin, administered to 66 infants
in stable condition, was successful in restoring normal sinus
rhythm in 58 (88%) and no deaths occurred. Therefore, in
the initial management of infants in stable condition with a
regular narrow QRS supraventricular tachycardia, digoxin
and electrical cardioversion (0.5 watt-s/kg) were both safe
and equally effective in this selective series of patients.
Direct current countershock remains the treatment of choice
for urgent conversion of life-threatening tachycardia. In the
future, the technique of esophageal pacing (22,23) may
become more widely available for use in the infant and
provide an alternative to electrical cardioversion.
The choice of medication for maintenance therapy in
these infants presents a more difficult problem. Mortality
associated with the use of digoxin in this patient group may
be at least 2%, and could be as high as 5%. In addition,
excessive amounts of digoxin may precipitate ventricular
fibrillation in these infants (24). Therefore, on the basis of
this experience, the use of digoxin in these patients may
carry a small but significant risk; the results of a multicenter
investigation now in progress may help clarify this issue.
Thus, in the absence of electrophysiologically demonstrated
safety of digoxin, the use of propranolol should be consid-
ered, particularly in the setting of recurrent supraventricular
tachycardia.
Recurrent supraventricular tachycardia. Among those
patients with significant recurrent episodes of typical supra-
ventricular tachycardia, other drugs such as propranolol,
quinidine or procainamide alone or in combination may be
necessary. Verapamil, effective in older patients, may be
used in older children, but experience with its use in infants
is limited. Bradycardia and hypotension have been reported
with use of verapamil in this age group (25); thus, if this
agent is used, pacing capabilities should be readily available.
In patients who manifest a wide QRS complex tachy-
cardia or atrial fibrillation, or both, the use of digitalis is
contraindicated. Wide QRS tachycardia appeared in three
of our patients, two of whom had Ebstein' s anomaly. Atrial
fibrillation occurred in only two patients in this series, in
one, a patient with Ebstein's anomaly, at age 24 years.
Drugs other than digitalis should be used in these patients
and electrophysiologic studies should be strongly considered.
We recommend electrophysiologic studies in addition for
those children older than I year of age in whom supraven-
tricular tachycardia is not adequately controlled by medical
management, to locate the bypass tract, to measure its re-
fractory period as well as that of the atrioventricular node
and to determine the response to medications, including
ouabain. Surgical division of the accessory connection is a
very effective method of treatment (26,27) and should be
considered as an alternative to life-long drug therapy in older
children.
On the basis of our experience, overall mortality, related
in part to arrhythmias, in patients with Wolff-Parkinson-
White syndrome and supraventricular tachycardia is 5% and
may be associated with heart disease in some cases. Ap-
proximately one-third of the patients will continue to have
recurrent supraventricular tachycardia after I year of age;
all patients presenting in infancy deserve long-term follow-
up.
We extend our thanks to Jane Newburger, MD. for statistical analysis and
to Barbara Cesaro and Mary Durkin for preparation of the manuscript.
References
I. Nadas AS, Daeschner CW, Roth A, Blumenthal SL. Paroxysmal
tachycardia in infants and children: study of 41 cases. Pediatrics
1952;9: 167-81.
2. Schiebler GL, Adams P, Anderson P, Anderson RC. The Wolff-
Parkinson-White syndrome in infants and children. A review and a
report of 28 cases. Pediatrics 1959;24:585-603.
3. Lundberg A. Paroxysmal tachycardia in infancy: follow-up study of
47 subjects ranging in age from 10-26 years. Pediatrics 1973;51:26-35.
4. Wolff GS, Han J, Curran J. Wolff-Parkinson-White syndrome in the
neonate. Am J Cardiol 1978;41:559-63.
5. Garson A Jr, Gillette PC, McNamara DG. Supraventricular tachy-
cardia in children: clinical features, response to treatment and long
term follow up in 217 patients. J Pediatr 1981;98:875-82.
6. Giardina CY, Ehlers KH, Engle MA. Wolff-Parkinson-White syn-
drome in infants and children: a long-term follow up study. Br Heart
J 1972;34:839-46.
7. Gallagher JJ, Gilbert M, Svenson RH, Sealy WC. Kasell J, Wallace
AG. Wolff-Parkinson-White syndrome: the problem, evaluation, and
surgical correction. Circulation 1975;51:767-85.
8. Smith WM, Gallagher JJ, Kerr CR, et al. The electrophysiologic basis
and management of symptomatic recurrent tachycardia in patients with
Ebstein's anomaly of the tricuspid valve. Am J Cardiol 1982;49:1223-34.
9. Wellens HJJ, Durrer D. Effect of digitalis on atrioventricular con-
duction and circus-movement tachycardias in patients with Wolff-
Parkinson-White syndrome. Circulation 1973;47: 1229-33.
JACC Vol. 5, No. I
January 1985:130-5
DEALET AL.
SUPRAVENTRICULAR TACHYCARDIA IN INFANCY
135
10. Swiderski J. Lees MH, Nadas AS. The Wolff-Parkinson-White syn-
drome in infancy and childhood. N Engl J Med 1962;267:968-74.
II. Mantakas ME. McCue CM, Miller WW. Natural history of Wolff-
Parkinson-White syndrome discovered in infancy. Am J Cardiol
1978;4 I: 1097-103.
12. Gillette PC, Garson A Jr. The preexcitation syndromes. In: Gillette
PC, Garson A Jr, eds. Pediatric Cardiac Dysrhythmias. New York:
Grune & Stratton, 1981:155.
13. Rosenbaum FF, Hecht HH, Wilson FN, Johnston FD. The potential
variations of the thorax and the esophagus in anomalous atrioventric-
ular excitation (Wolff-Parkinson-White syndrome). Am Heart J
1945;29:281-326.
14. Gillette PC, Garson A Jr, Kugler JD. Wolff-Parkinson-White syn-
drome in children: electrophysiologic and pharmacologic character-
istics. Circulation 1979;60: 1487-95.
15. Tonkin AM, Wagner GS, Gallagher 11, Cope GD, Kasell 1. Wallace
AG. Initial forces of ventricular depolarization in the Wolff-Parkinson-
White syndrome. Circulation 1975;52: 1030-5.
16. Becker AE, Anderson RH, Durrer D, Wellens H11. The anatomical
substrates of Wolff-Parkinson-White syndrome: a clinicopathologic
correlation in seven patients. Circulation 1978;57:870-9.
17. Mehta AV. Casta A. Wolff GS. Supraventricular tachycardia. In:
Roberts NK, Gelband H. eds. Cardiac Arrhythmias in the Neonate,
Infant and Child. Norwalk: Appleton-Century-Crofts. 1983:126.
18. Klein GJ, Bashore TM, Sellers TD, Pritchett ELC, Smith WM, Gal-
lagher 11. Ventricular fibrillation in the Wolff-Parkinson-White syn-
drome. N Engl J Med 1979;301:1080-5.
19. Cosio FG, Benson DW Jr. Anderson RW. et al. Onset of atrial fi-
brillation during antidromic tachycardia associated with sudden cardiac
arrest and ventricular fibrillation in a patient with Wolff-Parkinson-
White syndrome. Am J Cardiol 1982;50:353-9.
20. Jedeiken R, Gillette PC, Garson A Jr, et al. Effect of ouabain on the
anterograde effective refractory period of accessory atrioventricular
connections in children. J Am Coli Cardiol 1983;1:869-72.
21. Belhassen B. Pauzner D, Blieden L, et al. Intrauterine and postnatal
atrial fibrillation in the Wolff-Parkinson-White syndrome. Circulation
1982;66: 1124-8.
22. Gallagher JJ, Smith WM, Kerr CR, et al. Esophageal pacing: a di-
agnostic and therapeutic tool. Circulation 1982;65:336-41.
23. Benson DW. Dunnigan A, Benditt DG. Pritzker MR. Thompson TR.
Transesophageal study of infant supraventricular tachycardia: electro-
physiologic characteristics. Am J Cardiel 1983;52: 1002-6.
24. Byrum CH. Wahl RA, Behrendt DM, Dick M. Ventricular fibrillation
associated with use of digitalis in a newborn infant with Wolff-
Parkinson-White syndrome. J Pediatr 1982;101:400-3.
25. Soler-Soler J, Sagrista-Saulcda J, Cabrera A. et al. Effect of veraparnil
in infants with paroxysmal supraventricular tachycardia. Circulation
1979;59:876-9.
26. Sealy v«: Gallagher 11, Wallace AG. The surgical treatment of Wolff-
Parkinson-White syndrome: evolution of improved methods for iden-
tification and interruption of the Kent bundle. Ann Thorac Surg
1976;22:443-57.
27. Gillette PC. Garson A Jr. Kugler JD. Cooley DA. Zinner A, Mc-
Namara DG. Surgical treatment of supraventricular tachycardia in
infants and children. Am J Cardiol 1980;46:281-4.
